Mankind Pharma Limited
National Stock Exchange of IndiaTotal Valuation
Mankind Pharma Limited carries a market capitalization of 1.03T, placing it among publicly traded companies globally. Its enterprise value stands at 944.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.03T |
| Enterprise Value | 944.31B |
Valuation Ratios
Mankind Pharma Limited trades at a trailing price-to-earnings ratio of 49.89.
| PE Ratio | 49.89 |
| PS Ratio | 7.31 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Mankind Pharma Limited trades at an EV/EBITDA multiple of 38.45 and an EV/FCF ratio of 200.71. The EV/Sales ratio of 7.31 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 38.45 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.31 |
| EV / EBITDA | 38.45 |
| EV / EBIT | 38.45 |
| EV / FCF | 200.71 |
Financial Position
Mankind Pharma Limited maintains a current ratio of 4.18, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.89, indicating elevated leverage, while an interest coverage ratio of 4.17 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 4.18 |
| Quick Ratio | 2.04 |
| Debt / Equity | 62.89 |
| Debt / EBITDA | N/A |
| Interest Coverage | 4.17 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 372.04 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Mankind Pharma Limited has paid 4.83B in income taxes, reflecting an effective tax rate of 20.15.
| Income Tax | 4.83B |
| Effective Tax Rate | 20.15 |
Stock Price Statistics
Mankind Pharma Limited's stock has gained approximately 2.44685% over the past 52 weeks. The 50-day moving average sits at 2,419.07, while the 200-day moving average is 2,258.88.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2.44685% |
| 50-Day Moving Average | 2,419.07 |
| 200-Day Moving Average | 2,258.88 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mankind Pharma Limited generated 129.10B in revenue and converted that into 18.93B in net income, yielding earnings per share of 46.91. EBITDA reached 24.56B, while operating income came in at 24.56B.
| Revenue | 129.10B |
| Gross Profit | 91.77B |
| Operating Income | 24.56B |
| Pretax Income | 23.95B |
| Net Income | 18.93B |
| EBITDA | 24.56B |
| EBIT | 24.56B |
| Earnings Per Share (EPS) | 46.91 |
Margins
Mankind Pharma Limited operates with a gross margin of 71.08, reflecting its pricing power and cost economics. The operating margin of 19.02 and net profit margin of 14.66 provide insight into operational efficiency.
| Gross Margin | 71.08 |
| Operating Margin | 19.02 |
| Pretax Margin | 18.56 |
| Profit Margin | 14.66 |
| EBITDA Margin | 19.02 |
Scores
Mankind Pharma Limited posts an Altman Z-Score of 29.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 29.05 |